Compare Danaher Corporation (DHR) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Ralph Lauren Corp — how do they compare? Danaher Corporation trades at $207.85 (market cap $147.18B), while Ralph Lauren Corp trades at $399.17 (market cap $24.24B). The key difference: Danaher Corporation is far larger — about 6.1× Ralph Lauren Corp's market cap, and Ralph Lauren Corp pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| DHR | RL | |
|---|---|---|
Market Cap | $147.18B | $24.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $414.25 |
52-Week Low | $161.91 | $285.35 |
Enterprise Value | $169.39B | $25.31B |
Dividend Yield | 0.76% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $204.76, up 2.37% today, near its pivot point of $203 with bullish technical signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.92 EPS. Revenue for 2025 was $24.57B with a net income margin of 15.95%, though margins have trended down from 22.9% in 2022. Recent news includes the Masimo acquisition approval and a $172.5 million settlement over pandemic-era disclosures (Reuters, 2026-04-23).
Outlook is positive with strong analyst support (69% buy ratings) and a consensus price target of $202.33, slightly below current price. Risks include margin compression, high valuation (P/E 36.5), and integration challenges from acquisitions. Cash flow improved to $2.54B net in 2025 after a dip in 2023-2024, supporting dividend payments and growth initiatives.
Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.
The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
